SOM BIOTECH LICENSES ITS SOM0226 MEDICINE FOR AMYLOSIDES TO THE NORTH AMERICAN CORINA THERAPEUTICS

SOM Biotech - specializing in the repositioning of drugs to treat minority nervous system diseases - has signed a worldwide and exclusive licensing agreement with the North American company Corino Therapeutics for the clinical development and commercialization of the drug SOM0226 for the treatment of Transthyretin Amyloidosis (ATTR ). The operation was closed after the therapeutic agent discovered by the biopharmaceutical, based at the Parc Científic de Barcelona, ​​obtained very promising results in the Phase 2a clinical study. 

SOM Biotech has received an initial payment and will earn successive milestone and royalty revenues on the net sales of the product, in exchange for the exclusive global rights of SOM0226 (CRX-1008), which includes the use of the drug for all types of ATTR: Familial amyloid polyneuropathy, familial amyloid cardiomyopathy, senile, systemic and central nervous system (CNS) amyloidosis. 

"This licensing agreement provides a clear validation of the potential of the SOM Biotech business model. The fact that repositioned drugs have been widely used in their original indication allows people suffering from rare diseases and without any available treatment to obtain An accelerated development of safe treatment, "says Dr. Raúl Insa, executive director of SOM and adds:" SOM has found a great management team in Corino, which provides great security and experience to continue with the development of the program. This collaboration will allow us to expand our product portfolio in the near future and start Clinical Phase 2 of two new candidates for the treatment of other rare CNS diseases. " 

"At Corino Therapeutics we are excited to partner with SOM and its flagship program, SOM0226. Preclinical results and first clinical results demonstrate the potential of the drug to treat patients with all forms of ATTR. We look forward to the development of this promising drug, "says Corino's management team. 

Transthyre amyloidosis is a rare degenerative disease of genetic origin that mainly affects the nervous system and cardiac muscle tissue (myocardium). This disease originates when the liver and other areas of the organism produce the mutated transtiretine protein (TTR), thus losing its functional structure. This causes the accumulation of toxic aggregates in the form of amyloid fibers that, depending on the type of mutation, are deposited in different organs such as the brain, kidneys, peripheral nerves, eyes or myocardium, causing their malfunctioning and provoking the various forms of pathology . 

The therapeutic agent discovered by SOM through its in silico platform has been clinically validated in a Phase 2a proof-of-concept study in humans, carried out at the Vall d'Hebron Hospital in Barcelona. SOM0226 has obtained the designation of orphan drug by the FDA for all types of ATTR.